Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and α-hydroxytamoxifen

Cancer Letters

Volumn 257, Issue 2, 2007, Pages 191-198

  Gamboa da Costa, Gonçalo ^a,b   Marques, M Matilde ^a   Fu, Xin ^b   Churchwell, Mona I ^b   Wang, Yu Ping ^b   Doerge, Daniel R ^b   Beland, Frederick A ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

DNA adducts; N,N Didesmethyltamoxifen; Tamoxifen

Indexed keywords

4 HYDROXYNORTAMOXIFEN; 4 HYDROXYTAMOXIFEN; ALPHA HYDROXY N DESMETHYLTAMOXIFEN; ALPHA HYDROXYTAMOXIFEN; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A2; DRUG METABOLITE; N,N DIDESMETHYLTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TRIOCTANOIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; FEMALE; LIVER; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAMOXIFEN;

PRIMATES; RATTUS;

EID: 35048822885     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.014     Document Type: Article

References (46)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717.
2. Veronesi U., Maisonneuve P., Rotmensz N., Costa A., Sacchini V., Travaglini R., D'Aiuto G., Lovison F., Gucciardo G., Muraca M.G., Pizzichetta M.A., Conforti S., Decensi A., Robertson C., Boyle P., and the Italian Tamoxifen Study Group. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J. Natl. Cancer Inst. 95 (2003) 160-165
3. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., and Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97 (2005) 1652-1662
4. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A., and for the International Breast Cancer Intervention Study (IBIS) I investigators. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst. 99 (2007) 272-282
5. Powles T.J., Ashley S., Tidy A., Smith I.E., and Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl. Cancer Inst. 99 (2007) 283-290
6. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N., and for the Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies. J. Natl. Cancer Inst. 87 (1995) 645-651
7. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.-F., Cutuli B., Lasry S., Mauriac L., Granon C., Kerr C., Giard S., Hill C., de Lafontan B., de Gislain C., D'Anjou J., Fondrinier E., Lefeuvre C., Parache R.-M., Chauvin F., and on behalf of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int. J. Cancer 76 (1998) 325-330
8. Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E., Perlman J.A., and Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91 (1999) 1654-1662
9. Bergman L., Beelen M.L.R., Gallee M.P.W., Hollema H., Benraadt J., van Leeuwen F.E., and the Comprehensive Cancer Centres' ALERT Group. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356 (2000) 881-887
10. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18 (2003) 937-947
11. Swerdlow A.J., Jones M.E., and for the British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case - control study. J. Natl. Cancer Inst. 97 (2005) 375-384
12. Decensi A., Maisonneuve P., Rotmensz N., Bettega D., Costa A., Sacchini V., Salvioni A., Travaglini R., Oliviero P., D'Aiuto G., Gulisano M., Gucciardo G., Rosselli del Turco M., Pizzichetta M.A., Conforti S., Bonanni B., Boyle P., Veronesi U., and for the Italian Tamoxifen Study Group. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111 (2005) 650-656
13. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
14. White I.N.H. Anti-oestrogenic drugs and endometrial cancers. Toxicol. Lett. 120 (2001) 21-29
15. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., and Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56 (1996) 66-71
16. Gamboa da Costa G., Hamilton L.P., Beland F.A., and Marques M.M. Characterization of the major DNA adduct formed by α-hydroxy-N-desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol. 13 (2000) 200-207
17. Poirier M.C., and Schild L.J. The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis 18 (2003) 395-399
18. Hemminki K., Rajaniemi H., Lindahl B., and Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56 (1996) 4374-4377
19. Shibutani S., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., and Pearl M.L. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12 (1999) 646-653
20. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., and Pearl M.L. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21 (2000) 1461-1467
21. Martin E.A., Brown K., Gaskell M., Al-Azzawi F., Garner R.C., Boocock D.J., Mattock E., Pring D.W., Dingley K., Turteltaub K.W., Smith L.L., and White I.N.H. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63 (2003) 8461-8465
22. Carmichael P.L., Ugwumadu A.H.N., Neven P., Hewer A.J., Poon G.K., and Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56 (1996) 1475-1479
23. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20 (1999) 339-342
24. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl. Cancer Inst. 96 (2004) 1099-1104
25. Kim S.Y., Suzuki N., Laxmi Y.R.S., Rieger R., and Shibutani S. α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol. 16 (2003) 1138-1144
26. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16 (1995) 1651-1654
27. Phillips D.H., Carmichael P.L., Hewer A., Cole K.J., Hardcastle I.R., Poon G.K., Keogh A., and Strain A.J. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17 (1996) 89-94
28. Poon G.K., Walter B., Lønning P.E., Horton M.N., and McCague R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23 (1995) 377-382
29. Lien E.A., Solheim E., Lea O.A., Lundgren S., Kvinnsland S., and Ueland P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49 (1989) 2175-2183
30. Lien E.A., Solheim E., and Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51 (1991) 4837-4844
31. Comoglio A., Gibbs A.H., White I.N.H., Gant T., Martin E.A., Smith L.L., Gamalero S.R., and DeMatteis F. Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the Rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer?. Carcinogenesis 17 (1996) 1687-1693
32. Shibutani S., Suzuki N., Laxmi Y.R.S., Schild L.J., Divi R.L., Grollman A.P., and Poirier M.C. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res. 63 (2003) 4402-4406
33. Schild L.J., Divi R.L., Beland F.A., Churchwell M.I., Doerge D.R., Gamboa da Costa G., Marques M.M., and Poirier M.C. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res. 63 (2003) 5999-6003
34. Schild L.J., Phillips D.H., Osborne M.R., Hewer A., Beland F.A., Churchwell M.I., Brown K., Gaskell M., Wright E., and Poirier M.C. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods. Mutagenesis 20 (2005) 115-124
35. Gamboa da Costa G., Marques M.M., Freeman J.P., and Beland F.A. Synthesis and investigation of α-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen. Chem. Res. Toxicol. 16 (2003) 1090-1098
36. Gamboa da Costa G., McDaniel-Hamilton L.P., Heflich R.H., Marques M.M., and Beland F.A. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22 (2001) 1307-1315
37. Foster A.B., Jarman M., Leung O.-T., McCague R., Leclercq G., and Devleeschouwer N. Hydroxy derivatives of tamoxifen. J. Med. Chem. 28 (1985) 1491-1497
38. Williams L.D., Twaddle N.C., Churchwell M.I., and Doerge D.R. Quantification of tamoxifen and metabolites and soy isoflavones in human plasma using liquid chromatography with electrospray ionization tandem mass spectrometry. J. AOAC Int. 89 (2006) 1168-1173
39. Howard P.C., McManus M.E., and Koop D.R. The role of cytochrome P450 2C3 in rabbit liver microsomal metabolism of 1-nitropyrene and 3-nitrofluoranthene. J. Biochem. Toxicol. 9 (1994) 71-78
40. Cochin J., and Axelrod J. Biochemical and pharmacological changes in the rat following chronic administration of morphine, nalorphine and normorphine. J. Pharmacol. Exp. Ther. 125 (1959) 105-110
41. Fu X., Blaydes B.S., Weis C.C., Latendresse J.R., Muskhelishvili L., Sutter T.R., and Delclos K.B. Effects of dietary soy and estrous cycle on adrenal cytochrome P450 1B1 expression and DMBA metabolism in adrenal glands and livers in female Sprague-Dawley rats. Chem. Biol. Interact. 146 (2003) 273-284
42. 32P-postlabeling. Biochem. Biophys. Res. Commun. 320 (2004) 297-302
43. Mani C., Gelboin H.V., Park S.S., Pearce R., Parkinson A., and Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21 (1993) 645-656
44. Kasahara T., Hashiba M., Harada T., and Degawa M. Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 23 (2002) 491-498
45. Hashiba M., Kasahara T., Kim S.Y., Shibutani S., and Degawa M. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Cancer Sci. 97 (2006) 468-477
46. Gamboa da Costa G., Marques M.M., Beland F.A., Freeman J.P., Churchwell M.I., and Doerge D.R. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 16 (2003) 357-366